Skip to main content
. Author manuscript; available in PMC: 2022 Oct 14.
Published in final edited form as: Clin Cancer Res. 2022 Apr 14;28(8):1549–1559. doi: 10.1158/1078-0432.CCR-21-4049

Figure 2: Enzalutamide steady-state drug levels.

Figure 2:

Boxplot showing median, interquartile range, and full range of day 57/29 Enz and metabolite drug levels by dose escalation cohort. The Enz drug level trough drug concentration (Ctrough) achieved equivalent PK levels at a dosing of Enz 120 mg, Mif 300 mg with ratio of 1.0 for cohort 3, which became the recommended phase 2 dose. “X” denotes mean within each group.

Abbreviations: Ctrough, concentration of Enz and metabolite on given day; Enz, enzalutamide; Mif, mifepristone.